Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	7.85T +244.9%
Revenue (ttm)	5.08B +0.2%
Net Income	-87.46B
EPS	-1,074.77
Shares Out	83.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	647,883
Average Volume	621,907
Open	97,000
Previous Close	99,900
Day's Range	91,000 - 98,700
52-Week Range	29,350 - 110,900
Beta	-0.67
RSI	58.35
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.